Eli Lilly and Company News - November 1, 2026

Lilly's Next-Gen Drug Crushes Ozempic in Head-to-Head Trial — But Can It Justify a Trillion-Dollar Valuation?
LLY

Lilly's Next-Gen Drug Crushes Ozempic in Head-to-Head Trial — But Can It Justify a Trillion-Dollar Valuation?

Shares of Eli Lilly surged +4.4% to $1,344.79 after the company reported that its experimental injectable, retatrutide, demolished Novo Nordisk's Ozempic in...